篇名

新冠肺炎之中醫治療與藥物研發   免費試閱

並列篇名

The TCM Treatment and Drug Development of COVID-19

作者
中文摘要

2020年「新型冠狀病毒病」(下簡新冠肺炎)全球大流行,成為本世紀最嚴重的公衛議題,雖然全球已投入大量資源進行研發,但迄今尚無有效的疫苗與治療藥物。新冠肺炎屬於中醫「疫病」,在中醫傳統理論與2003年SARS治療經驗下,國家中醫藥研究所提出「新型冠狀病毒病中醫臨床分期治療指引」,並與四所醫學中心合作治癒21位患者,同時完成標的方劑「台灣清冠一號」(NRICM101)研發,並授權藥廠製造及取得外銷許可證,將可對國際社會提供積極協助。

英文摘要

In 2020, the global pandemic of COVID-19 has become the most serious public health issue of this century. Although the world has invested a lot of resources in research and development, there are no effective vaccines and therapeutic medicine so far. In traditional Chinese medicine, COVID-19 belongs to the disease “疫”, based on the traditional Chinese medicine theory and the experience of SARS treatment in 2003, the National Research Institute of Chinese Medicine (NRICM) proposed the “Guideline for the Clinical Staging and Treatment of COVID-19 in Traditional Chinese Medicine” and cooperated with four medical centers to cure 21 patients. At the same time, NRICM completed the research and development of the target formula “NRICM101”, and authorized the pharmaceutical factory to manufacture and obtain the export license. We believe “NRICM101” will provide positive assistance to the international community.

起訖頁

007-016

出版單位
DOI

10.3966/241553062020100048001  複製DOI  DOI查詢

QRCode

數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP